Press release
Esophageal Cancer Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Oncolys BioPharma Inc, Genentech, OncoTherapy Science, Shionogi, CStone Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Esophageal Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.
The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Esophageal Cancer Pipeline Report: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.
• Esophageal Cancer companies working in the treatment market are Lyvgen Biopharma, Eli Lilly and Company, Zymeworks, Jazz Pharmaceuticals, Amgen, CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment
• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- LVGN-6051, CYRAMZA (ramucirumab), Zanidatamab, Bemarituzumab, CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.
• In May 2024, The FDA has granted orphan drug designation to 9MW2821, a novel Nectin-4-targeted ADC, for the treatment of esophageal cancer patients. Developed by Mabwell using its ADC platform and automated high-throughput hybridoma antibody molecular discovery platform, 9MW2821 is the first site-specific conjugated ADC targeting Nectin-4. The agent utilizes a unique linker technology and streamlined conjugation process to precisely modify antibodies, allowing them to target and bind to Nectin-4. Several trials of 9MW2821 have been conducted in China to assess its safety, tolerability, pharmacokinetic characteristics, and efficacy in patients with various advanced solid tumors.
• In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA® (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.
• In February 2024, Elevation Oncology, Inc. (Nasdaq: ELEV), a forward-thinking oncology company dedicated to developing targeted cancer therapies for patients with various solid tumors and significant unmet needs, has announced the expansion of its ongoing Phase 1 clinical trial of EO-3021 beyond the United States. The first patient has been dosed in Japan. The trial aims to assess the safety, tolerability, and initial anti-tumor effects of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors that are likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, and esophageal cancers.
Esophageal Cancer Overview
Esophageal cancer is a type of cancer that forms in the tissues of the esophagus, the muscular tube that carries food and liquids from the mouth to the stomach. The two main types of esophageal cancer are squamous cell carcinoma, which occurs in the cells lining the esophagus, and adenocarcinoma, which often develops in the lower part of the esophagus near the stomach. Risk factors include smoking, heavy alcohol consumption, obesity, and gastroesophageal reflux disease (GERD). Symptoms may include difficulty swallowing, chest pain, unexplained weight loss, and persistent heartburn. Early detection is crucial, and treatment options include surgery, radiation, chemotherapy, and targeted therapy, depending on the cancer's stage.
Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:
• LVGN-6051: Lyvgen Biopharma
• CYRAMZA (ramucirumab): Eli Lilly and Company
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Bemarituzumab: Amgen
• CDR404: CDR-Life Inc.
• M1231: Merck KGaA
• Sotigalimab: Apexigen
• Amivantamab: Genmab
• Telomelysin: Oncolys BioPharma Inc
• Tiragolumab: Genentech
• S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.
• CS1001: CStone Pharmaceuticals
• Durvalumab: Celgene/MedImmune
• Tucatinib: Seagen
• APX 005M: Apexigen
• Erdafitinib: Janssen Research & Development, LLC
• Margetuximab: MacroGenics
• AN-0025: Adlai Nortye
Esophageal Cancer Route of Administration
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Esophageal Cancer Molecule Type
Esophageal Cancer Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Esophageal Cancer Pipeline Therapeutics Assessment
• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage and Product Type
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer By Stage and Route of Administration
• Esophageal Cancer Assessment by Molecule Type
• Esophageal Cancer by Stage and Molecule Type
DelveInsight's Esophageal Cancer Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Esophageal Cancer Therapeutics Market include:
Key companies developing therapies for Esophageal Cancer are - Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.
Esophageal Cancer Pipeline Analysis:
The Esophageal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Esophageal Cancer Pipeline Market Drivers
• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.
Esophageal Cancer Pipeline Market Barriers
• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.
Scope of Esophageal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Esophageal Cancer Companies: Lyvgen Biopharma, Eli Lilly and Company, Zymeworks, Jazz Pharmaceuticals, Amgen, CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others
• Key Esophageal Cancer Therapies: LVGN-6051, CYRAMZA (ramucirumab), Zanidatamab, Bemarituzumab, CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers
Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Esophageal Cancer Report Introduction
2. Esophageal Cancer Executive Summary
3. Esophageal Cancer Overview
4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment
5. Esophageal Cancer Pipeline Therapeutics
6. Esophageal Cancer Late Stage Products (Phase II/III)
7. Esophageal Cancer Mid Stage Products (Phase II)
8. Esophageal Cancer Early Stage Products (Phase I)
9. Esophageal Cancer Preclinical Stage Products
10. Esophageal Cancer Therapeutics Assessment
11. Esophageal Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Esophageal Cancer Key Companies
14. Esophageal Cancer Key Products
15. Esophageal Cancer Unmet Needs
16 . Esophageal Cancer Market Drivers and Barriers
17. Esophageal Cancer Future Perspectives and Conclusion
18. Esophageal Cancer Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Esophageal Cancer Market https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Esophageal Cancer Epidemiology https://www.delveinsight.com/report-store/esophageal-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Esophageal Cancer Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Oncolys BioPharma Inc, Genentech, OncoTherapy Science, Shionogi, CStone Pharma here
News-ID: 3825987 • Views: …
More Releases from DelveInsight Business Research

Malt Lymphoma Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Malt Lymphoma pipeline constitutes 10+ key companies continuously working towards developing 12+ Malt Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Malt Lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malt Lymphoma Market.
The Malt…

AIDS Related Kaposi's Sarcoma Market Growth to Accelerate in Forecast Period (20 …
DelveInsight's "AIDS Related Kaposi's Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the AIDS Related Kaposi's Sarcoma, historical and forecasted epidemiology as well as the AIDS Related Kaposi's Sarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of AIDS Related Kaposi's Sarcoma, offering comprehensive insights into the AIDS…

Biliary Tumor Market Set to Grow Substantially Through 2032, DelveInsight Projec …
DelveInsight's "Biliary Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Tumor, historical and forecasted epidemiology as well as the Biliary Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Biliary Tumor, offering comprehensive insights into the Biliary Tumor revenue trends, prevalence, and treatment landscape. The…

Chronic Inflammatory Demyelinating Polyneuropathy Market to Show Remarkable Grow …
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy, historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Inflammatory Demyelinating Polyneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for Esophageal
Esophageal Catheter Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Esophageal Catheter Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Esophageal Catheter market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,…
Esophageal Catheter Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Esophageal Catheter Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Esophageal Catheter players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Esophageal Catheter with respect to individual growth…
Esophageal Cancer-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer-Pipeline…
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017
"The Report Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Gastric and Esophageal Cancer Drug Development Market
This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these…
Overview Of The Esophageal Cancer Market - Pipeline Review, H2 2017
"The Latest Research Report Esophageal Cancer-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Esophageal Cancer Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer-Pipeline Review, H2 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or…
Global Gastrointestinal Stents (Esophageal, Duodenal/Pyloric And Colorectal) Mar …
SA-BRC announces the release of its report on “Non-Vascular Stents Market Assessment & Forecast: 2015 - 2019”.
The global gastrointestinal stents (esophageal, duodenal/pyloric and colorectal) market is forecast to reach US$118.9 million in 2015 according to the new report “Non-Vascular Stents Market Assessment & Forecast: 2015 - 2019” by SA-Business Research & Consulting group.
There are primarily three groups of stents that comprise the total global non-vascular stents. The report includes analysis…